Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 9, 2021, Mr. Tae Heum (Ted) Jeong provided notice of his resignation
from the Board of Directors (the "Board") of NeuroBo Pharmaceuticals, Inc. (the
"Company"), effective immediately. Dr. Jeong's resignation was not the result of
any disagreement with the Company regarding the Company's operations, policies
or practices. In connection with the resignation of Dr. Jeong, the Board reduced
the size of the Board from eight members to seven members.
On January 11, 2021, Douglas J. Swirsky, a current director of the Company was
elected Chairman of the Board and appointed Chairman of the Audit Committee.
Mr. Jeong Gyun Oh, a current director of the Company was appointed to the Audit
Committee. The Board has determined that each of Mr. Swirsky and Mr. Oh are
independent in accordance with the listing standards of Nasdaq and the Company's
internal policies, and that each otherwise meets all applicable requirements to
serve on the Audit Committee, including the rules and regulations of the
Securities and Exchange Commission ("SEC"). In addition, the Board has
determined that each of Mr. Swirsky and Mr. Oh qualify as an "audit committee
financial expert" pursuant to SEC rules and regulations.
On January 11, 2021, Nicola Shannon resigned as the Company's Vice President of
Clinical Operations effective January 22, 2021.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses